18F-PSMA-1007 is a fluorine-18-labeled PSMA-targeting diagnostic radiopharmaceutical indicated for PET imaging of PSMA-positive lesions in adults with persistent or biochemical recurrent prostate cancer. A radioactive imaging agent given by injection before a PET scan to help locate prostate cancer that has come back after treatment.
- Mechanism
- Curator reviewed · 4 references
[18F]PSMA-1007 is a diagnostic agent consisting of a Glu-urea-Lys PSMA-targeting moiety radiolabeled with fluorine-18. It binds PSMA with high nanomolar affinity; PSMA is characteristically overexpressed 100 to 1000-fold in prostate cancer compared with normal organs and tissues. [18F]PSMA-1007 is internalized after binding, which enhances its accumulation in prostate cancer cells. Fluorine-18 is a positron (β+)-emitting radionuclide that allows imaging by PET/CT.
- Primary indication
- Canada [18F]PSMA-1007 is indicated for the imaging of prostate-specific membrane antigen (PSMA) positive lesions by positron emission tomography (PET) in adults with persistent or biochemical recurrent (BCR) prostate cancer, based on elevated serum prostate-specific antigen...Curator reviewed · 2 structured indications
- Also known as
- Fluorine-18 PSMA 1007
- Code names
- 18F-PSMA-1007 · PSMA-1007
Resolves to
What you can answer from here — as of October 28, 2026
Which drugs share a target with 18F-PSMA-1007, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account